Congress commits $6B to subsidize antibiotic makers—with a twist.

What it does

This bill creates a $6 billion federal program to pay pharmaceutical companies $75–$300 million per year for developing new antibiotics targeting drug-resistant infections. Companies must apply within 2 years of FDA approval, meet scoring criteria based on clinical benefit and innovation, maintain U.S. supply, track resistance data, and educate providers on appropriate use. The program also funds hospital and outpatient antibiotic stewardship programs and expands CDC surveillance of resistance trends.

Why we flagged it

The bill's operative mechanism is a guaranteed annual payment to drug manufacturers ($75–$300M per year, adjusted for inflation, reduced only by net U.S. sales). While framed as addressing antimicrobial resistance—a real public-health crisis—the payment structure is a de facto subsidy that decouples company revenue from market performance, shifting development risk to taxpayers.

What the text implies

• The payment formula (annual subsidy minus net U.S. sales revenue) creates a perverse incentive: companies profit most when they sell less, because the government payment remains high while sales revenue is subtracted. A company selling $50M in a year receives $225M–$250M in government payment; one selling $200M receives $75M–$100M. This inverts normal market discipline.
• Section 399PP–1(2) exempts the Advisory Group from FACA termination rules (Section 1013), meaning the committee has no automatic sunset and may persist indefinitely without congressional reauthorization, reducing oversight of the program's scoring and eligibility decisions.
• The bill allows the Secretary to waive standard federal contracting rules 'as the Secretary may determine to be inconsistent with the furtherance of the purposes of this part' (399PP, Authority vested in the Secretary), granting broad discretion to bypass procurement safeguards.
• Confidentiality provisions (399PP, Disclosure of information) prohibit disclosure of manufacturer pricing, discounts, rebates, or net revenue data, shielding companies from public scrutiny of how government subsidies interact with their commercial pricing strategies.
• Contract terms end when a generic or biosimilar is approved using the subsidized drug as the reference, but the bill does not require the company to license or facilitate generic entry, potentially allowing indefinite monopoly pricing while collecting government payments.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Citizens gain access to new antibiotics for resistant infections and stewardship programs that reduce inappropriate use, addressing a genuine public-health crisis. However, the payment structure—a guaranteed annual subsidy decoupled from sales volume—transfers financial risk from companies to taxpayers while allowing companies to retain full commercial revenue, creating a form of corporate welfare that may inflate public costs without proportional public benefit.

Who stands to gain

• pharmaceutical companies developing antimicrobial drugs
• biopharmaceutical manufacturers of novel antibiotics and antifungals

Named in the bill

U.S. Department of Health and Human Services (Secretary), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), Centers for Medicare & Medicaid Services (CMS), Critical Need Antimicrobial Advisory Group, Biomedical Advanced Research and Development Authority (BARDA), National Healthcare Safety Network (NHSN), AMR Industry Alliance, BSI Standards Limited

Where it stands

29 cosponsors: 17 Democrats, 12 Republicans.

• Feb 4, 2026 — Introduced · Congress.gov: “Introduced in House”
• Feb 4, 2026 — Referred to House Committee on the Budget and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Budget, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

7 lobbying clients named this bill on 7 disclosure filings across 2 quarters, Mar 2026 to Jun 2026. Those filings disclosed $1,160,000 in lobbying spend. A filing names 8 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 86% of bills with at least one filing.

Buddy Carter, the sponsor, reported $988,325 in PAC receipts in the 2026 cycle.

• Cormedix Inc. — $380,000 on 1 filing
• Cystic Fibrosis Foundation — $270,000 on 1 filing
• Dh Diagnostics, LLC — $220,000 on 1 filing
• Association for Diagnostics & Laboratory Medicine (formerly Aacc) — $120,000 on 1 filing
• Dh Diagnostics LLC — $70,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.